Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Conatus Pharmaceuticals (CNAT) Competitors

Conatus Pharmaceuticals logo

CNAT vs. SCPS, EVLO, CMRA, ARDS, STAB, AMPE, CLVR, EFTR, HSTO, and MTEM

Should you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and Molecular Templates (MTEM). These companies are all part of the "medical" sector.

Conatus Pharmaceuticals vs. Its Competitors

Conatus Pharmaceuticals (NASDAQ:CNAT) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Conatus Pharmaceuticals has higher revenue and earnings than Scopus BioPharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conatus Pharmaceuticals$21.72M0.00-$11.39MN/AN/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Conatus Pharmaceuticals has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.

In the previous week, Conatus Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Conatus Pharmaceuticals Neutral
Scopus BioPharma Neutral

Scopus BioPharma has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Scopus BioPharma's return on equity of 0.00% beat Conatus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Conatus Pharmaceuticals-52.42% -48.22% -39.32%
Scopus BioPharma N/A N/A N/A

15.2% of Conatus Pharmaceuticals shares are held by institutional investors. 11.3% of Conatus Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Conatus Pharmaceuticals beats Scopus BioPharma on 5 of the 8 factors compared between the two stocks.

Get Conatus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNAT vs. The Competition

MetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$10K$784.70M$5.45B$8.93B
Dividend YieldN/A4.84%5.22%4.01%
P/E Ratio0.001.3027.2420.06
Price / Sales0.00230.50426.37117.54
Price / CashN/A23.4426.2128.59
Price / Book0.006.237.925.56
Net Income-$11.39M-$27.94M$3.17B$248.56M

Conatus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNAT
Conatus Pharmaceuticals
N/A$0.00
flat
N/A-99.9%$10K$21.72M0.0030
SCPS
Scopus BioPharma
N/A$0.00
-97.0%
N/AN/A$13KN/A0.009
EVLO
Evelo Biosciences
N/A$0.00
flat
N/AN/A$9KN/A0.00120
CMRA
Comera Life Sciences
N/A$0.00
flat
N/AN/A$6K$1.00M0.002
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat
N/AN/A$5K$3.09M0.0030
STAB
Statera Biopharma
N/A$0.00
flat
N/A-83.3%$5KN/A0.0020
AMPE
Ampio Pharmaceuticals
0.142 of 5 stars
$0.00
flat
N/AN/A$3KN/A0.0020
CLVR
Clever Leaves
N/A$0.00
flat
N/AN/A$1K$17.42M0.00560
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat
N/A-99.8%$1K$3.55M0.0010Gap Down
HSTO
Histogen
N/A$0.00
-25.0%
N/A-99.9%$1K$19K0.0020
MTEM
Molecular Templates
N/AN/AN/AN/A$1K$23.48M0.00260

Related Companies and Tools


This page (NASDAQ:CNAT) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners